HUP0203559A3 - Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them - Google Patents
Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- HUP0203559A3 HUP0203559A3 HU0203559A HUP0203559A HUP0203559A3 HU P0203559 A3 HUP0203559 A3 HU P0203559A3 HU 0203559 A HU0203559 A HU 0203559A HU P0203559 A HUP0203559 A HU P0203559A HU P0203559 A3 HUP0203559 A3 HU P0203559A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- polymorphic forms
- sertraline hydrochloride
- Prior art date
Links
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960003660 sertraline hydrochloride Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99810981 | 1999-10-29 | ||
PCT/EP2000/010416 WO2001032601A1 (en) | 1999-10-29 | 2000-10-23 | Polymorphic forms of sertraline hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203559A2 HUP0203559A2 (hu) | 2003-03-28 |
HUP0203559A3 true HUP0203559A3 (en) | 2008-01-28 |
Family
ID=8243113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203559A HUP0203559A3 (en) | 1999-10-29 | 2000-10-23 | Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them |
Country Status (17)
Country | Link |
---|---|
US (2) | US6872853B1 (hu) |
EP (1) | EP1224160B1 (hu) |
JP (1) | JP2003513062A (hu) |
CN (1) | CN1384816A (hu) |
AR (1) | AR026293A1 (hu) |
AT (1) | ATE409684T1 (hu) |
AU (1) | AU1386301A (hu) |
CA (1) | CA2387135A1 (hu) |
DE (1) | DE60040406D1 (hu) |
HU (1) | HUP0203559A3 (hu) |
IL (2) | IL149050A0 (hu) |
MX (1) | MXPA02004255A (hu) |
MY (1) | MY141509A (hu) |
TR (1) | TR200201146T2 (hu) |
TW (1) | TWI260315B (hu) |
WO (1) | WO2001032601A1 (hu) |
ZA (1) | ZA200203254B (hu) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1133459B1 (en) * | 1998-11-27 | 2006-01-11 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride form v |
EP1632473A1 (en) * | 1998-11-27 | 2006-03-08 | Teva Pharmaceutical Industries Ltd | Sertraline hydrochloride polymorphs |
US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
US6495721B1 (en) | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
US7442838B2 (en) * | 1999-10-29 | 2008-10-28 | Ciba Specialty Chemicals Corp. | Polymorphic forms of sertraline hydrochloride |
US20050119351A1 (en) * | 1999-10-29 | 2005-06-02 | Van Der Schaaf Paul A. | Polymorphic forms of sertraline hydrochloride |
EP1774965A3 (en) * | 1999-12-21 | 2007-10-10 | Teva Pharmaceutical Industries Ltd | Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them |
HUP0204010A3 (en) * | 1999-12-21 | 2006-02-28 | Teva Pharma | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use |
IN192343B (hu) * | 2000-05-26 | 2004-04-10 | Ranbaxy Lab Ltd | |
EP1397343A1 (en) * | 2001-05-31 | 2004-03-17 | Orion Corporation Fermion | Process for preparing sertraline hydrochloride polymorphic form ii |
WO2003093217A1 (en) * | 2002-04-29 | 2003-11-13 | Teva Pharmaceutical Industries Ltd. | Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
KR101161935B1 (ko) * | 2002-06-27 | 2012-07-03 | 인터디지탈 테크날러지 코포레이션 | 사용자 장치 측정값 정보를 피어 투 피어 방식으로 교환하는 무선 네트워크 제어기 |
US7186863B2 (en) | 2003-05-23 | 2007-03-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
RU2376279C2 (ru) | 2003-11-04 | 2009-12-20 | Сипла Лимитед | Способ получения полиморфов ингибитора повторного захвата серотонина (варианты) |
US20070173536A1 (en) * | 2004-02-06 | 2007-07-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of zolmitriptan |
US20070100165A1 (en) * | 2005-06-09 | 2007-05-03 | Ronen Borochovitz | Process for preparation of sertraline hydrochloride form I |
US7518019B2 (en) | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
CA2594198A1 (en) * | 2007-07-20 | 2009-01-20 | Apotex Pharmachem Inc. | A novel process for the preparation of sertraline hydrochloride form ii |
US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
WO2012138690A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
CN103458859A (zh) | 2011-04-07 | 2013-12-18 | 宝洁公司 | 具有增强的聚丙烯酸酯微胶囊的沉积的个人清洁组合物 |
WO2012138696A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Shampoo compositions with increased deposition of polyacrylate microcapsules |
CN105061217A (zh) * | 2015-06-30 | 2015-11-18 | 徐静 | 枸橼酸舍曲林的2种晶型及其制备方法 |
CN112552188B (zh) * | 2020-12-17 | 2023-07-28 | 山西仟源医药集团股份有限公司 | 盐酸舍曲林晶型i的制备方法 |
CN113588626B (zh) * | 2021-08-24 | 2024-05-24 | 上海师范大学 | 一种苯丙氨酸对映体的拉曼光谱检测方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US5082970A (en) | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
GB9114947D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline |
US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US5734083A (en) | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
HU222341B1 (hu) | 1996-12-18 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier |
DE69713353D1 (de) * | 1997-12-11 | 2002-07-18 | Torcan Chemical Ltd | Sertralin-Polymorph mit verbesserter Wasserlöslichkeit |
PT1064250E (pt) | 1998-03-18 | 2004-09-30 | Ciba Sc Holding Ag | Processo para a hidrogenacao catalitica cis-selectiva ciclo-hexilidenaminas |
JP2000026378A (ja) | 1998-07-03 | 2000-01-25 | Sumika Fine Chemicals Co Ltd | 塩酸セルトラリンの製法 |
US6500987B1 (en) | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
EP1133459B1 (en) | 1998-11-27 | 2006-01-11 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride form v |
US6495721B1 (en) | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
HUP0204010A3 (en) | 1999-12-21 | 2006-02-28 | Teva Pharma | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use |
-
2000
- 2000-10-07 TW TW089120975A patent/TWI260315B/zh not_active IP Right Cessation
- 2000-10-20 MY MYPI20004969A patent/MY141509A/en unknown
- 2000-10-23 AU AU13863/01A patent/AU1386301A/en not_active Abandoned
- 2000-10-23 JP JP2001534755A patent/JP2003513062A/ja not_active Withdrawn
- 2000-10-23 IL IL14905000A patent/IL149050A0/xx active IP Right Grant
- 2000-10-23 HU HU0203559A patent/HUP0203559A3/hu unknown
- 2000-10-23 EP EP00975896A patent/EP1224160B1/en not_active Expired - Lifetime
- 2000-10-23 US US10/111,947 patent/US6872853B1/en not_active Expired - Fee Related
- 2000-10-23 AT AT00975896T patent/ATE409684T1/de not_active IP Right Cessation
- 2000-10-23 TR TR2002/01146T patent/TR200201146T2/xx unknown
- 2000-10-23 CA CA002387135A patent/CA2387135A1/en not_active Abandoned
- 2000-10-23 WO PCT/EP2000/010416 patent/WO2001032601A1/en active IP Right Grant
- 2000-10-23 DE DE60040406T patent/DE60040406D1/de not_active Expired - Fee Related
- 2000-10-23 MX MXPA02004255A patent/MXPA02004255A/es active IP Right Grant
- 2000-10-23 CN CN00815052A patent/CN1384816A/zh active Pending
- 2000-10-27 AR ARP000105711A patent/AR026293A1/es not_active Application Discontinuation
-
2002
- 2002-04-09 IL IL149050A patent/IL149050A/en not_active IP Right Cessation
- 2002-04-24 ZA ZA200203254A patent/ZA200203254B/xx unknown
-
2003
- 2003-12-15 US US10/736,195 patent/US6939992B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6872853B1 (en) | 2005-03-29 |
JP2003513062A (ja) | 2003-04-08 |
US20040132828A1 (en) | 2004-07-08 |
CN1384816A (zh) | 2002-12-11 |
TWI260315B (en) | 2006-08-21 |
EP1224160B1 (en) | 2008-10-01 |
WO2001032601A1 (en) | 2001-05-10 |
MY141509A (en) | 2010-05-14 |
DE60040406D1 (de) | 2008-11-13 |
MXPA02004255A (es) | 2002-10-17 |
TR200201146T2 (tr) | 2004-12-21 |
IL149050A (en) | 2007-03-08 |
HUP0203559A2 (hu) | 2003-03-28 |
US6939992B2 (en) | 2005-09-06 |
AR026293A1 (es) | 2003-02-05 |
IL149050A0 (en) | 2002-11-10 |
AU1386301A (en) | 2001-05-14 |
ZA200203254B (en) | 2003-07-22 |
EP1224160A1 (en) | 2002-07-24 |
CA2387135A1 (en) | 2001-05-10 |
ATE409684T1 (de) | 2008-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203559A3 (en) | Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them | |
HUP0200758A3 (en) | Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them | |
HUP0203257A3 (en) | Polymorphic forms of atorvastatin calcium, process for their preparations and pharmaceutical compositions containing them | |
HUP0105108A3 (en) | Amide compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0203669A3 (en) | Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0204245A3 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203316A3 (en) | Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0204010A3 (en) | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use | |
AU4465200A (en) | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them | |
HUP0400236A3 (en) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride, process for their preparation and pharmaceutical compositions containing them | |
HUP0200572A3 (en) | Amine derivatives as protease inhibitors process for their preparation, pharmaceutical compositions containing them and their use | |
AU2953699A (en) | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them | |
HUP0102723A3 (en) | New diphenylurea derivatives, process for their preparation and pharmaceutical compositions containing them | |
IL162456A0 (en) | A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochlor | |
HUP0201516A3 (en) | 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0200881A3 (en) | Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use | |
HUP0201753A2 (en) | Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0200580A3 (en) | Polymorphic crystalline forms of celecoxib, process their preparation and pharmaceutical compositions containing them | |
HUP0201402A3 (en) | Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them | |
HUP0203184A3 (en) | Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0401163A3 (en) | L crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation and pharmaceutical compositions containing the crystalline forms | |
HUP0204318A3 (en) | Torsemide polymorphic forms, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0202934A3 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof | |
HUP0202731A3 (en) | O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
IL164903A0 (en) | Processes for preparation of polymorphic form II of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |